Satellos Bioscience (NASDAQ:MSLE) Now Covered by Guggenheim

Key Points

• Guggenheim initiated coverage with a "buy" rating and a $23.00 price target, implying about a 221% upside from the stock's current level.
• Overall analyst picture is mixed but positive: MarketBeat shows a consensus rating of "Moderate Buy" with a consensus price target of $18.00 (four Buys, one Hold, one Sell).
• Shares trade around $7.16 with a market cap of $149.1M and negative earnings (missed last quarter and projected ~-2.04 EPS for the year); the company is developing an oral therapeutic for Duchenne muscular dystrophy.

Stock analysts at Guggenheim initiated coverage on shares of Satellos Bioscience (NASDAQ:MSLE - Get Free Report) in a research report issued to clients and investors on Tuesday. The brokerage set a "buy" rating and a $23.00 price target on the stock. Guggenheim's price objective suggests a potential upside of 221.23% from the company's current price.

Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald started coverage on shares of Satellos Bioscience in a report on Wednesday, March 11th. They set an "overweight" rating on the stock. Zacks Research raised shares of Satellos Bioscience to a "hold" rating in a research note on Tuesday, February 10th. HC Wainwright raised their target price on shares of Satellos Bioscience to $11.00 and gave the company a "buy" rating in a research note on Monday, March 30th. Wall Street Zen lowered shares of Satellos Bioscience from a "sell" rating to a "strong sell" rating in a research note on Saturday. Finally, Weiss Ratings initiated coverage on shares of Satellos Bioscience in a research note on Wednesday, February 11th. They issued a "sell (d-)" rating on the stock. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Satellos Bioscience has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.

Satellos Bioscience Trading Up 2.6%

Shares of NASDAQ:MSLE opened at $7.16 on Tuesday. Satellos Bioscience has a 12 month low of $4.53 and a 12 month high of $13.39. The stock's 50-day moving average is $8.54. The company has a market cap of $149.14 million, a price-to-earnings ratio of -4.62 and a beta of 1.37.

Satellos Bioscience (NASDAQ:MSLE - Get Free Report) last issued its quarterly earnings data on Friday, March 27th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.11). As a group, analysts expect that Satellos Bioscience will post -2.04 EPS for the current year.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.